LGALS1 and neoplasm: Blocking gal-1 and gal-3 with peptide- and carbohydrate-derived or small-molecule-specific inhibitors revealed a restraining effect on tumor growth, angiogenesis, and metastasis in preclinical as well as clinical studies (reviewed in [194]).